BR112023022439A2 - Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular - Google Patents

Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular

Info

Publication number
BR112023022439A2
BR112023022439A2 BR112023022439A BR112023022439A BR112023022439A2 BR 112023022439 A2 BR112023022439 A2 BR 112023022439A2 BR 112023022439 A BR112023022439 A BR 112023022439A BR 112023022439 A BR112023022439 A BR 112023022439A BR 112023022439 A2 BR112023022439 A2 BR 112023022439A2
Authority
BR
Brazil
Prior art keywords
drug compound
implantable device
core
sustained release
macromolecular drug
Prior art date
Application number
BR112023022439A
Other languages
English (en)
Inventor
Christian Schneider
Dirk Hair
Harsh Patel
C Haley Jeffrey
Vijay Gyanani
Original Assignee
Celanese Eva Performance Polymers Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celanese Eva Performance Polymers Llc filed Critical Celanese Eva Performance Polymers Llc
Publication of BR112023022439A2 publication Critical patent/BR112023022439A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A61K8/0233—Distinct layers, e.g. core/shell sticks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0241—Containing particulates characterized by their shape and/or structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8135—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an acyloxy radical of a saturated carboxylic acid, of carbonic acid or of a haloformic acid; Compositions of derivatives of such polymers, e.g. vinyl esters (polyvinylacetate)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/54—Polymers characterized by specific structures/properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/60—Particulates further characterized by their structure or composition
    • A61K2800/65—Characterized by the composition of the particulate/core
    • A61K2800/652—The particulate/core comprising organic material

Abstract

dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular. trata-se de um dispositivo implantável para administração de um composto de fármaco macromolecular. o dispositivo compreende um núcleo que tem uma superfície externa e uma camada de membrana posicionada adjacente à superfície externa do núcleo. o núcleo compreende uma matriz polimérica de núcleo dentro da qual é disperso um composto de fármaco que tem um peso molecular de cerca de 0,5 kda ou mais, sendo que a matriz polimérica contém um polímero hidrofóbico. além disso, a camada de membrana compreende uma pluralidade de partículas solúveis em água distribuídas dentro de uma matriz polimérica de membrana que contém um copolímero de etileno e acetato de vinila, em que as partículas solúveis em água têm um tamanho de partícula d50 de cerca de 150 micrômetros ou menos e contêm um composto não polimérico hidroxifuncional.
BR112023022439A 2021-04-26 2022-04-21 Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular BR112023022439A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163179620P 2021-04-26 2021-04-26
US202163252287P 2021-10-05 2021-10-05
US202263300767P 2022-01-19 2022-01-19
US202263311517P 2022-02-18 2022-02-18
PCT/US2022/025688 WO2022231930A1 (en) 2021-04-26 2022-04-21 Implantable device for sustained release of a macromolecular drug compound

Publications (1)

Publication Number Publication Date
BR112023022439A2 true BR112023022439A2 (pt) 2023-12-26

Family

ID=83848559

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023022439A BR112023022439A2 (pt) 2021-04-26 2022-04-21 Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular

Country Status (6)

Country Link
EP (1) EP4329734A1 (pt)
JP (1) JP2024515220A (pt)
BR (1) BR112023022439A2 (pt)
CA (1) CA3216832A1 (pt)
TW (1) TW202308598A (pt)
WO (1) WO2022231930A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006055008A2 (en) * 2003-11-20 2006-05-26 Angiotech International Ag Implantable sensors and implantable pumps and anti-scarring agents
RU2541104C2 (ru) * 2008-01-30 2015-02-10 Новартис Аг Препаративная форма с замедленным высвобождением, содержащая октреотид и три линейных полимера поли(лактид-со-гликолида)
JP2019524833A (ja) * 2016-08-17 2019-09-05 ユープラシア ファーマシューティカルズ インク． 抗生物質を含む薬物の持続的局所送達
WO2018045058A1 (en) * 2016-08-30 2018-03-08 Dana-Farber Cancer Institute, Inc. Drug delivery compositions and uses thereof
SG11202005947RA (en) * 2018-05-24 2020-07-29 Celanese Eva Performance Polymers Corp Implantable device for sustained release of a macromolecular drug compound

Also Published As

Publication number Publication date
CA3216832A1 (en) 2022-11-03
EP4329734A1 (en) 2024-03-06
WO2022231930A1 (en) 2022-11-03
JP2024515220A (ja) 2024-04-05
TW202308598A (zh) 2023-03-01

Similar Documents

Publication Publication Date Title
Jia et al. Nanotoxicity of different sizes of graphene (G) and graphene oxide (GO) in vitro and in vivo
Patel et al. Development of oral sustained release rifampicin loaded chitosan nanoparticles by design of experiment
Asthana et al. Immunoadjuvant chemotherapy of visceral leishmaniasis in hamsters using amphotericin B-encapsulated nanoemulsion template-based chitosan nanocapsules
Saha et al. Formulation and evaluation of chitosan-based ampicillin trihydrate nanoparticles
MX2020012458A (es) Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular.
BRPI0924543B8 (pt) composição farmacêutica de liberação controlada, e seu processo de preparação
BRPI0807569A8 (pt) Péletes compreendendo uma matriz de substância ativa resistentes ao suco gástrico
BRPI0614080A2 (pt) Composição e método para a preparação de uma cefalosporina nanoparticulada, para o tratamento de doença bacteriana e para a prevenção e/ou tratamento de osteoporose
CA3045888C (en) Color tone controlled curable composition
BR112023022439A2 (pt) Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
BR112019018032A2 (pt) Composição fotocurável e material de preenchimento para restauração dentária
Musmade et al. Methotrexate-loaded biodegradable nanoparticles: preparation, characterization and evaluation of its cytotoxic potential against U-343 MGa human neuronal glioblastoma cells
PH12019500947A1 (en) Pharmaceutical compositions and uses thereof
BR112017001186A2 (pt) dispersão de poli(acetato de vinil) e formulação de tinta compreendendo a mesma
Bahmani et al. Fabrication of poly (ϵ‐caprolactone)/paclitaxel (core)/chitosan/zein/multi‐walled carbon nanotubes/doxorubicin (shell) nanofibers against MCF‐7 breast cancer
Andretto et al. Nanoemulsions Embedded in Alginate Beads as Bioadhesive Nanocomposites for Intestinal Delivery of the Anti-Inflammatory Drug Tofacitinib
BR112018009028A8 (pt) misturas poliméricas para uso em estrutura multicamadas e estruturas multicamadas compreendendo as mesmas
Lee et al. Oral administration of microbiome-friendly graphene quantum dots as therapy for colitis
Jena et al. Cytotoxicity and pharmacokinetic studies of PLGA based capecitabine loaded nanoparticles
Akhlaq et al. Carvacrol-fabricated chitosan nanoparticle synergistic potential with topoisomerase inhibitors on breast and cervical cancer cells
BR112017023873A2 (pt) composição curável para filme de barreira acústica
PE20091271A1 (es) Nanoparticulas con superficie modificada
Barman et al. In vivo pharmacokinetic and hemocompatible evaluation of lyophilization induced nifedipine solid-lipid nanoparticle
BR112018015624A2 (pt) forma de dosagem oral de película de loxapina
Lee et al. Marbofloxacin-encapsulated microparticles provide sustained drug release for treatment of veterinary diseases